Hematology/Oncology

Top Story

Radiotherapy shows potential role in treatment of Hodgkin lymphoma subtype

Radiotherapy shows potential role in treatment of Hodgkin lymphoma subtype
November 17, 2017

Radiotherapy prolonged OS among patients with all stages of nodular lymphocytic Hodgkin lymphoma, including those with B-symptoms, according to study results.

However, patients with advanced-stage disease and B-symptoms appeared unlikely to undergo radiotherapy, results also showed.

Meeting News

High compliance with Optune linked to greatest survival benefit for glioblastoma

November 17, 2017
Patients with newly diagnosed glioblastoma who used the Optune device more than 90% of the time had the greatest chance for survival, according to a company-issued press…

ASCO expands enrollment for TAPUR study

November 17, 2017
ASCO announced four cohorts of Targeted Agent and Profiling Utilization Registry, or TAPUR, will enroll additional patients with a variety of cancers. The combination of…
Meeting NewsVideo

VIDEO: Physicians should take special considerations for metastatic renal cell carcinoma management

November 17, 2017
MIAMI Saby George, MD, FACS, offered background in special considerations that should be taken when treating patients with metastatic renal cell carcinoma at…

Liver tumor program launched to ‘work in a fashion of teamwork’

November 17, 2017
The Perlmutter Cancer Center at NYU Langone Health launched a new liver tumor program, designed to provide multidisciplinary care for patients with primary and secondary…
More Headlines »
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News

VIDEO: Ipilimumab-nivolumab emerges as new standard for metastatic renal cell carcinoma

November 15, 2017
More »
Resource Centers

CME

Expert Perspectives: The Latest Evidence Regarding Immune Checkpoint Inhibitors for Advanced Bladder Cancer

This activity is supported by an educational grant from Merck & Co., Inc.

In 2016, the first immune checkpoint inhibitor was approved by the US Food and Drug Administration (FDA) for the…
More »
Current Issues
View the Current Issue
HemOnc Today